New cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07429721
Summary
This is an early-stage study to test the safety and initial effectiveness of a new cell therapy called QI-019A in adults with multiple myeloma that has come back or stopped responding to standard treatments. The therapy involves modifying a patient's own immune cells to target the cancer. Researchers will give the treatment to 24 participants at a single hospital to check for side effects and see if it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.